Targeted & controlled bone healing
  • slidebg1
  • slidebg1
  • slidebg1
Kuros has spent more than a decade refining technologies that instruct the body to form bone using targeted and controlled mechanisms of action.

Kuros Biosciences are experts in the science of orthobiologics.

Our technology platforms aim to deliver improved patient outcomes through targeted and controlled bone healing.

We are poised to realise this aim through the launch of MagnetOs, based on our flagship surface science technology, and through the expansion of our portfolio by the continued clinical development of products based on our novel TG Hook technology.

Latest News
10 Dec 18
Kuros receives FDA 510(k) clearance for extending commercial indications of MagnetOs Putty in the United States
US Food and Drug Administration (FDA) clearance granted for extending the use of MagnetOs Putty as a stand-alone bone graft in extremities and pelvis . Paves way for commercial expansion into more clinical indications in orthopedic surgery . READ MORE


06 Dec 18
Kuros reports publication of MagnetOs data demonstrating equivalence to autologous bone in spinal fusion
Study should further enhance competitive positioning of MagnetOs . Sheep animal model is one of the most relevant preclinical model and believed to be predictive of outcomes in humans . 12-week fusion rate with MagnetOs granules & putty 92% & 83% versus autograft 75% . READ MORE


Kuros Biosciences AG
Wagistrasse 25, 8952 Schlieren, Switzerland
Tel: +41 44 733 47 47   Fax: +41 44 733 47 40   Email: info@kurosbio.com

About Kuros

  1. Overview
  2. Executive Committee
  3. Board
  4. Careers

Products

  1. MagnetOs

Pipeline

  1. Pipeline
  2. Spinal fusion
    KUR-113
  3. Fracture repair
    KUR-111
    KUR-113
  4. Surgical Sealants
    Neuroseal (KUR-023)

Technologies

  1. Surface Science Technology
  2. Fibrin-Based
  3. Synthetic Cross-Linking Technology
  4. Immune Modulation

Partnerships

  1. Collaborations
  2. Business Development

Investors

  1. Share price
  2. Regulatory filings
  3. Reports & Presentations
  4. Analysts
  5. Calendar
  6. Corporate governance
  7. Stay informed

News

  1. Press releases
  2. Conferences & Events

Contact

  1. Location
Kuros has spent more than a decade refining technologies that instruct the body to form bone using targeted and controlled mechanisms of action.

Kuros Biosciences are experts in the science of orthobiologics.

Our technology platforms aim to deliver improved patient outcomes through targeted and controlled bone healing.

We are poised to realise this aim through the launch of MagnetOs, based on our flagship surface science technology, and through the expansion of our portfolio by the continued clinical development of products based on our novel TG Hook technology.

Latest News
10 Dec 18
Kuros receives FDA 510(k) clearance for extending commercial indications of MagnetOs Putty in the United States
US Food and Drug Administration (FDA) clearance granted for extending the use of MagnetOs Putty as a stand-alone bone graft in extremities and pelvis . Paves way for commercial expansion into more clinical indications in orthopedic surgery . READ MORE


06 Dec 18
Kuros reports publication of MagnetOs data demonstrating equivalence to autologous bone in spinal fusion
Study should further enhance competitive positioning of MagnetOs . Sheep animal model is one of the most relevant preclinical model and believed to be predictive of outcomes in humans . 12-week fusion rate with MagnetOs granules & putty 92% & 83% versus autograft 75% . READ MORE